Meetings

Conference abstracts

81 public abstracts from 2021 to 2026. Findings are the abstract’s own wording. Level 1 items, where ctDNA or MRD assigned treatment or surveillance, have a coral bar. Slide and poster links, when added, may require an ASCO or ESMO member login.

1 abstracts

Level 3prognosticASCO Annual Meeting 2022
Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC.
Flach, Susanne · Abstract 6017 · LIONESS · 35 patients, 236 longitudinal plasma samples; prospective observational; median follow-up 9.5 months at this report
RaDaR (personalized panels targeting a median of 48 somatic variants, range 20-60)
Baseline (pre-surgery) ctDNA detection was 94.28%. Recurrence occurred in 8/11 (72.7%) patients who were ctDNA-positive during follow-up vs 0/24 who were ctDNA-negative (P=7e-7). In all 8 clinical recurrences, ctDNA was detected first, with lead times of 56 to 265 days. Post-surgery ctDNA was detected at variant allele fractions as low as 0.0005%.

Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC.